Brokers Offer Predictions for MediWound FY2029 Earnings

MediWound Ltd. (NASDAQ:MDWD) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for MediWound in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth anticipates that the biopharmaceutical company will post earnings of $2.45 per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share.

MediWound (NASDAQ:MDWD) last released its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23. The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the company earned ($0.19) earnings per share.

A number of other equities analysts have also recently weighed in on the company. StockNews.com raised MediWound to a “sell” rating in a research note on Friday. Craig Hallum began coverage on MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 price target on the stock.

MediWound Stock Down 4.6 %

NASDAQ:MDWD opened at $16.27 on Friday. The business’s 50-day moving average price is $18.17 and its 200 day moving average price is $17.59. The firm has a market cap of $175.60 million, a P/E ratio of -5.61 and a beta of 0.82. MediWound has a 52-week low of $12.78 and a 52-week high of $24.00.

Hedge Funds Weigh In On MediWound

A number of institutional investors have recently bought and sold shares of MDWD. Investor AB acquired a new stake in MediWound during the 3rd quarter worth about $15,750,000. Yelin Lapidot Holdings Management Ltd. boosted its position in MediWound by 13.4% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after acquiring an additional 100,618 shares during the period. Essex Investment Management Co. LLC boosted its position in MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after acquiring an additional 35,012 shares during the period. Northern Trust Corp boosted its position in MediWound by 94.6% during the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after acquiring an additional 70,367 shares during the period. Finally, Sargent Investment Group LLC boosted its position in MediWound by 3.4% during the 4th quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company’s stock worth $2,217,000 after acquiring an additional 3,998 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.